Trial Profile
PD-1 Immune Checkpoint Inhibition for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers With or Without a History of Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Therapeutic Use
- 02 Feb 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 02 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 17 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.